Literature DB >> 28646693

Antibacterial effect of genetically-engineered bacteriophage ϕEf11/ϕFL1C(Δ36)PnisA on dentin infected with antibiotic-resistant Enterococcus faecalis.

Justine Monnerat Tinoco1, Nadia Liss2, Hongming Zhang3, Roni Nissan2, Wanda Gordon2, Eduardo Tinoco4, Luciana Sassone5, Roy Stevens3.   

Abstract

OBJECTIVE: Enterococcus faecalis is a gram-positive facultative anaerobic bacterium, which is present in 30-89% of teeth with postendodontic treatment failures. E. faecalis is capable of penetrating dentinal tubules and surviving as a monoculture after conventional endodontic therapy, indicating that it is resistant to commonly used endodontic disinfection protocols. Different E. faecalis strains have shown resistance to several antibiotics, and have been associated with both dental pathology and systemic infections. The aim of this study was to evaluate the efficacy of a genetically engineered bacteriophage to disinfect dentin infected with antibiotic resistant strains of E. faecalis.
METHODS: Extracted human dentin root segments were cemented into sealable two-chamber devices, fabricated from syringe needle caps to form in vitro infected-dentin models. The models were inoculated with an overnight suspension of either E. faecalis V583 (vancomycin resistant strain) or E. faecalis JH2-2 (fusidic acid and rifampin resistant, vancomycin sensitive strain). After 7days of incubation at 37°C, a suspension of a genetically engineered phage, ϕEf11/ϕFL1C(Δ36)PnisA, was added to the root canal of each infected dentin segment, and the incubation was continued for an additional 72-h. Dentin was harvested from the walls of each root canal and assayed for the residual titer of E. faecalis cells.
RESULTS: The recovered E. faecalis titer was reduced by 18% for the JH2-2 infected models, and by 99% for the V583 infected models.
CONCLUSION: Treatment: of E. faecalis-infected dentin with bacteriophage ϕEf11/ϕFL1C(Δ36)PnisA consistently resulted in a decrease in the residual bacterial population of both vancomycin-sensitive and resistant strains.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial; Bacteriophage; Dentin infection; Enterococcus faecalis phage therapy

Mesh:

Substances:

Year:  2017        PMID: 28646693     DOI: 10.1016/j.archoralbio.2017.06.005

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  5 in total

Review 1.  Phage Therapy in the Era of Multidrug Resistance in Bacteria: A Systematic Review.

Authors:  Carlos Aranaga; Lady Daniela Pantoja; Edgar Andrés Martínez; Aura Falco
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 2.  Molecular mechanisms of enterococcal-bacteriophage interactions and implications for human health.

Authors:  Gregory S Canfield; Breck A Duerkop
Journal:  Curr Opin Microbiol       Date:  2020-07-08       Impact factor: 7.934

3.  Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.

Authors:  Małgorzata Łobocka; Krystyna Dąbrowska; Andrzej Górski
Journal:  BioDrugs       Date:  2021-04-21       Impact factor: 5.807

Review 4.  Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases.

Authors:  Hao-Ming Xu; Wen-Min Xu; Long Zhang
Journal:  Int J Clin Pract       Date:  2022-10-03       Impact factor: 3.149

5.  Drug resistance of oral bacteria to new antibacterial dental monomer dimethylaminohexadecyl methacrylate.

Authors:  Suping Wang; Haohao Wang; Biao Ren; Xiaodong Li; Lin Wang; Han Zhou; Michael D Weir; Xuedong Zhou; Radi M Masri; Thomas W Oates; Lei Cheng; Hockin H K Xu
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.